Anúncio
Anúncio

OTLK

OTLK logo

Outlook Therapeutics, Inc. Common Stock

0.59
USD
Patrocinado
+0.06
+10.86%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

0.57

-0.01
-2.39%

Relatórios de Lucros OTLK

Rácio de surpresa positiva

OTLK separação 18 de 35 últimas estimativas.

51%

Próximo Relatório

Data do Próximo Relatório
12 de fev. de 2026
Estimate for Q1 26 (Revenue/ EPS)
$3.88M
/
-$0.18
Mudanças implicadas de Q4 25 (Revenue/ EPS)
-4313.04%
/
-5.26%
Mudanças implicadas de Q1 25 (Revenue/ EPS)
--
/
-125.00%

Outlook Therapeutics, Inc. Common Stock earnings per share and revenue

On 19 de dez. de 2025, OTLK reported earnings of -0.19 USD per share (EPS) for Q4 25, beating the estimate of -0.25 USD, resulting in a 26.47% surprise. Revenue reached -92000, compared to an expected 5.97 milhão, with a -101.54% difference. The market reacted with a -2.90% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analistas forecast an EPS of -0.18 USD, with revenue projected to reach 3.88 milhão USD, implying an diminuir of -5.26% EPS, and diminuir of -4313.04% in Revenue from the last quarter.
FAQ
For Q4 2025, Outlook Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 26.47%, and revenue of $-92.00K, -101.54% below expectations.
The stock price moved down -2.9%, changed from $2.07 before the earnings release to $2.01 the day after.
The next earning report is scheduled for 12 de fev. de 2026.
Based on 4 analistas, Outlook Therapeutics, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $3.88M for Q1 2026.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio